Ado-Trastuzumab Emtansine
Brand Names: Kadcyla
Methodology & AI Transparency ⓘ
Ado-Trastuzumab Emtansine Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: 1 Indications and usage kadcyla: is a HER2-targeted antibody and microtubule inhibitor conjugate indicated, as a single agent, for: the treatment of patients with HER2-positive, metastatic breast cancer who previously received trastuzumab and a taxane, separately or in combination.
- 2 Real-world patient consensus: Zero-PHI community consensus: 87% favorable across 10 logged regimens (Kadcyla).
- 3 Typical cash cost range: Uninsured 30-day outlay compares $79.38 cash mean against $194.48 retail pharmacy pricing.
- 4 Top reported side effects / signs: Key post-marketing and trial adverse reactions (Ado-Trastuzumab Emtansine): nausea (11.5%), headache (10.1%), fatigue (5.6%).
Ask our AI Specialists anything about Ado-Trastuzumab Emtansine
Ado-Trastuzumab Emtansine Mechanism, CYP450 Pathways & DailyMed Monograph
1 Indications and usage kadcyla: is a HER2-targeted antibody and microtubule inhibitor conjugate indicated, as a single agent, for: the treatment of patients with HER2-positive, metastatic breast cancer who previously received trastuzumab and a taxane, separately or in combination. Patients should have either: received prior therapy for metastatic disease, or developed disease recurrence during or within six months of completing adjuvant therapy.
12.1 Mechanism of Action Ado-trastuzumab emtansine is a HER2-targeted antibody-drug conjugate. The antibody is the humanized anti-HER2 IgG1, trastuzumab. The small molecule cytotoxin, DM1, is a microtubule inhibitor. Upon binding to sub-domain IV of the HER2 receptor, ado-trastuzumab emtansine undergoes receptor-mediated internalization and subsequent lysosomal degradation, resulting in intracellular release of DM1-containing cytotoxic catabolites. Binding of DM1 to tubulin disrupts microtubule networks in the cell, which results in cell cycle arrest and apoptotic cell death.
Following administration (20 mg/mL Injection, Powder, Lyophilized, for Solution), Ado-Trastuzumab Emtansine achieves Complete (~100%) parenteral systemic delivery for Ado-Trastuzumab Emtansine (20 mg/mL Injection, Powder, Lyophilized, for Solution) bioavailability and rapid intravascular/parenteral onset within 15–45 minutes after ado-trastuzumab emtansine administration onset, governed by a Mean elimination half-life of 10 to 23 hours across adult Ado-Trastuzumab Emtansine dosing terminal half-life through biotransformed through cyp3a4 pathways with mixed urinary/fecal clearance.
Before initiating Ado-Trastuzumab Emtansine at 20 mg/mL Injection, Powder, Lyophilized, for Solution, clinical safety checklists rule out contraindicated in patients with prior serious allergic response to ado-trastuzumab emtansine (ndc 50242-087); severe baseline organ impairment where ado-trastuzumab emtansine accumulation exceeds safe therapeutic margins. Logged tolerability patterns center on nausea (11.5% of reports), headache (10.1% of reports), constipation (6% of reports).
Azole antifungals or ritonavir can markedly raise Ado-Trastuzumab Emtansine plasma peaks; dose reduction may be warranted.
Co-prescribing strong CYP3A4 inhibitors or inducers can modify Ado-Trastuzumab Emtansine metabolic elimination kinetics.
Standard Adult Titration & Dosages
Absolute & Relative Contraindications
- Contraindicated in patients with prior serious allergic response to Ado-Trastuzumab Emtansine (NDC 50242-087)
- Severe baseline organ impairment where Ado-Trastuzumab Emtansine accumulation exceeds safe therapeutic margins
Logged Side-Effect Incidence (10 Reports)
Ado-Trastuzumab Emtansine Real-World Side Effects: openFDA FAERS vs. Patient Micro-Logs
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Ado-Trastuzumab Emtansine)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| Can This Approach Help? Inside the Latest Research on Efficacy, Safety, how the body absorbs the medicine and Immunogenicity of UJVIRA Results demonstrated biosimilarity between UJVIRA and Kadcyla in terms of efficacy, safety, how the body absorbs the medicine, and immunogenicity. Clinical breast cancer • 2022-06-15 • Phase III Randomized Trial | N = 168 | 82/100 | PMID 34955432 ↗ |
Ado-Trastuzumab Emtansine Public Price Transparency Ledger
| Dispensing Channel / Benchmark | Verification Source | Reference Cost | Details |
|---|---|---|---|
| Pharmacy Acquisition Cost (CMS NADAC) | CMS Medicaid NADAC Weekly National Survey | $1.7500/unit (~$52.50/30u) | Wholesale baseline |
| Average U.S. Walk-In Retail Cash Price | Chain Pharmacy Uninsured Cash Index | $194.48 / mo | Before coupon/insurance |
| Patient-Logged Out-of-Pocket Average | 10 Anonymous DotMD Community Micro-Logs | $79.38 / mo | View logs ↓ |
Ado-Trastuzumab Emtansine Federal Verification & Benchmark Summary
| Metric | Verified Benchmark | Source |
|---|---|---|
| Ado-Trastuzumab Emtansine RxNorm Concept ID | 1658084 | U.S. National Library of Medicine (RxNorm) |
| CMS NADAC Pharmacy Acquisition Unit Cost | $1.7500 / unit | CMS Medicaid NADAC Weekly Feed |
| Walk-In Chain Pharmacy Cash Average | $194.48 / mo | U.S. Uninsured Retail Cash Index |
| Public Mail-Order Wholesale Benchmark | $79.38 / mo (Patient Mean) | Public Cash Reference |
| Real-World Patient Consensus | 87.00% Worth It (10 anonymous logs) | DotMD Zero-PHI Patient Ledger |
Ado-Trastuzumab Emtansine Patient Community, Cohort Filters & Dosage Logs
Deterministic Ado-Trastuzumab Emtansine reference combining NIH RxNorm (1658084), Medicaid NADAC ($1.7500/unit), and anonymous cohort outcomes (87% Worth It).
Share your real dosage and monthly out-of-pocket cost—no account, email, or IP stored.
Filter Ado-Trastuzumab Emtansine community threads and patient logs by age, biological sex, dosage, and treatment duration.